eCite Digital Repository
The Future of Schizophrenia Psychopharmacotherapy: More Antipsychotic Atypicality? Guess So!
Citation
Naguy, A and Pridmore, S and Alamiri, B, The Future of Schizophrenia Psychopharmacotherapy: More Antipsychotic Atypicality? Guess So!, Psychopharmacology Bulletin, 53, (1) pp. 55-57. ISSN 0048-5764 (2023) [Contribution to Refereed Journal]
Abstract
No single neurotransmitter aberration could explain the heterogeneity of schizophrenia syndrome and thus, treatment strategies capitalizing solely on a single neurotransmitter system (e.g., DA blockade) is less likely to be fully successful on clinical grounds. Hence, there is a pressing need to develop newer antipsychotics above and beyond DA antagonism. In this regard, authors brief on five agents that sound pretty promising and might usher in a new sparkle in the psychopharmacotherapy of schizophrenia. This paper is a sequel for authors' previous article on future of schizophrenia psychopharmacotherapy.
Item Details
| Item Type: | Contribution to Refereed Journal |
|---|---|
| Keywords: | brilaroxazine; emraclidine; evenamide; ralmitaront; roluperidone; schizophrenia |
| Research Division: | Biomedical and Clinical Sciences |
| Research Group: | Clinical sciences |
| Research Field: | Psychiatry (incl. psychotherapy) |
| Objective Division: | Health |
| Objective Group: | Public health (excl. specific population health) |
| Objective Field: | Mental health |
| UTAS Author: | Pridmore, S (Professor Saxby Pridmore) |
| ID Code: | 155758 |
| Year Published: | 2023 |
| Deposited By: | Medicine |
| Deposited On: | 2023-03-14 |
| Last Modified: | 2023-03-14 |
| Downloads: | 0 |
Repository Staff Only: item control page